$Novavax(NVAX)$Novavax blamed the reduced sales guidance on alack of new Covid-19 vaccine salesin the U.S. It also cited poor sales resulting from the company’s international alliance, Covax, which targets vaccines in developing nations. While FDA approval of Novavax’s Covid-19 vaccine was viewed positively by analysts and investors, it arrived toward the end of the pandemic. More than 75% of U.S. adults are already fully vaccinated against the respiratory disease. The U.S. government has only ordered about three million doses of the Novavax vaccine for use this coming fall and winter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments